About us
SEEDSUPPLY: Pioneering the Future of Drug Discovery
SEEDSUPPLY is a cutting-edge drug discovery support company revolutionizing the identification of hit compounds that lead to first-in-class drugs. Established in 2017 as a spin-off from Takeda, SEEDSUPPLY has become a global leader in precision-driven compound screening, accelerating breakthroughs in pharmaceutical research.
Our core expertise lies in Improved Affinity Selection Mass Spectrometry, a proprietary technology that enables direct binding analysis of membrane proteins in their native state, without solubilization. This is a game-changer in drug discovery, as it preserves the natural conformation and function of SLC transporters, GPCRs, and other critical yet challenging drug targets, allowing for more physiologically relevant screening. Beyond membrane proteins, SEEDSUPPLY also performs large-scale binding protein screening with over 17,000 proteins, offering a powerful platform to uncover novel drug targets and mechanisms of action. Combined with our unique library of 400,000 compounds, this enables unparalleled efficiency in target determination and lead compound identification, even for previously undruggable targets.
Leadership
-
Naoki Tarui, Ph.D.
CEO
Dr. Tarui has been involved in drug discovery research especially hit finding for 20 years at Takeda Pharmaceutical Company. A typical hit compound is the seed compound of vonoprazan (the world's first potassium competitive acid blocker).
Dr. Tarui has established SEEDSUPPLY as spin-out from Takeda in 2017 to improve the early drug discovery process for small molecule drugs by using binder selection technology.
Dr. Tarui has advocated a groundbreaking drug discovery that leverages the binder collection. -
Management Team
| Director, Research & Planning | Masaharu Nakayama |
|---|---|
| Director | Yusuke Nakamura |
- SEEDSUPPLY is a supplier of drug seeds located in Shonan Research Park in Fujisawa, Japan.
-
